购物车
- 全部删除
- 您的购物车当前为空
MN-25 (compound 4a) 是一种可口服的吲哚吡啶酮,作为新型大麻素配体。其针对CB1和CB2的Ki分别为245 nM和11 nM。MN-25 展示出CB2激动剂活性,能够在体外抑制人外周血单核细胞中TNF-R的释放,IC50为33 μM。然而,在小鼠急性炎症模型中,以口服剂量高达50 mg/kg时未显示出疗效。
MN-25 (compound 4a) 是一种可口服的吲哚吡啶酮,作为新型大麻素配体。其针对CB1和CB2的Ki分别为245 nM和11 nM。MN-25 展示出CB2激动剂活性,能够在体外抑制人外周血单核细胞中TNF-R的释放,IC50为33 μM。然而,在小鼠急性炎症模型中,以口服剂量高达50 mg/kg时未显示出疗效。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 期货 | |
50 mg | 询价 | 期货 |
产品描述 | MN-25 (compound 4a) is an orally active indole pyridinone that functions as a novel cannabinoid ligand. It exhibits binding affinities (Ki) of 245 nM for CB1 and 11 nM for CB2 receptors. As a CB2 agonist, MN-25 inhibits TNF-R release from human peripheral blood mononuclear cells in vitro, with an IC50 of 33 μM. However, in an acute inflammation model in mice, MN-25 did not demonstrate efficacy at oral doses up to 50 mg/kg. |
靶点活性 | CB2:11 nM (Ki), CB1:254 nM (Ki) |
分子量 | 439.59 |
分子式 | C26H37N3O3 |
CAS No. | 501926-82-5 |
存储 | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
评论内容